Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)
- Günter Emons*
- , Grigor Gorchev
- , Jalid Sehouli
- , Pauline Wimberger
- , Anne Stähle
- , Lars Hanker
- , Felix Hilpert
- , Herbert Sindermann
- , Carsten Gründker
- , Philipp Harter
*Corresponding author for this work
- Department of Obstetrics and Gynecology
- Georg August University Göttingen
- University Hospital Dr. Gregory Stranski
- Charite - Universitatsmedizin Berlin
- University of Duisburg-Essen
- Universitätsklinikum Carl Gustav Carus
- St. Vincentius Kliniken Karlsruhe
- University of Kiel
- Æterna Zentaris GmbH
- Dr. Horst Schmidt Klinik GmbH
- Kliniken Essen-Mitte
51
Link opens in a new tab
Citations
(Scopus)